BioSpace News Archive

Clinical Trial Design Announced for SEQUOIA-HCM, Phase 3 Clinical Trial of Aficamten Expected to Begin in Q4 Company Details Plan for Developing a Cardiovascular Franchise

Antios Therapeutics, Inc. today announced that Chief Executive Officer, Gregory Mayes and Chief Medical Officer and Co-Founder, Douglas Mayers , M.D., will participate alongside other leaders in HBV at the H.C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Virtual Conference.

Enveric Biosciences today announced that Dr. Joseph Tucker , Chief Executive Officer of Enveric Biosciences, will participate in two upcoming October conferences: A.G.P.'s Biotech & Specialty Pharma Conference to be held virtually on Wednesday, October 13, 2021.

NeonMind Biosciences Inc. today announced that Robert Tessarolo , President and Chief Executive Officer, will present live at the KCSA Psychedelics Virtual Investor Conference.

DTx Pharma, Inc. today announced that Dr. Arthur Suckow, Co-Founder and CEO, and Denise Bevers, COO, will participate in the 8th Annual Virtual Solebury Trout Fall Private Company Showcase 2021 co-hosted with BMO on October 14, 2021.

ITOCO INC. (OTC Pink:ITMC) ITOCO representatives will be presenting to and attending the meeting session COP 26, Glasgow, UK, from 25 Oct 2021 to 12 Nov 2021.

Eledon Pharmaceuticals, Inc. announced their participation in the Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) which is being held virtually on October 7, 2021.

Avid Bioservices, Inc., a dedicated biologics contract development and manufacturing organization working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, announced the appointment of Matthew Kwietniak as chief commercial officer.

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the Company will present preclinical data on its progress in the development of cell therapy medicines for the treatment of cancer at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting being held in Washington, D.C., and virtually, November 10-14, 2021.

Science 37, Inc., the Operating System for today’s agile clinical trials, announced today that it has completed its previously announced business combination with LifeSci Acquisition II Corp. (NASDAQ: LSAQ) (“LifeSci”), a blank check company targeting the biopharma, medical technology, digital health and healthcare services sectors.